Surrogate scores of advanced fibrosis in NAFLD/NASH do not predict mortality in patients with medium-to-high cardiovascular risk

• DOI: 10.1152/ajpgi.00058.2021
• Publication Date: 2021-06-16T12:00:55Z
• Authors: Graciela E. Delgado; Marcus E. Kleber; Angela P. Moissl; Babak Yazdani; Alexander Kusnik; Matthias P. Ebert; Winfried März; Bernhard K. Krämer; Alexander Lammert; Andreas Teufel
• Keywords: Adult; Liver Cirrhosis; Male; Health Status; Middle Aged; Coronary Angiography; Prognosis; Risk Assessment; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Liver Function Tests; Cardiovascular Diseases; Heart Disease Risk Factors; Non-alcoholic Fatty Liver Disease; Predictive Value of Tests; Cause of Death; Humans; Female; Prospective Studies; Aged

We investigated the impact of NAFLD surrogate markers in a large cohort of patients that had been referred to coronary angiography. In contrast to a repeatedly demonstrated increased link of cardiovascular events in patients with NALFD, we demonstrated that NAFLD surrogate markers were not independent risk factors for overall or cardiovascular mortality in patients with CAD. Thus, these markers may not be useful for primary prevention of cardiovascular events in patients with CAD.